596226 Disclosed herein is a pharmaceutical antitumor combination including cabazitaxel and capecitabine, wherein both of said antitumor agents may be in the form of a base, in the form of a pharmaceutically acceptable acid salt or in the form of a hydrate or solvate, intended for the treatment of metastatic breast cancer in patients progressing after a previous treatment with anthracyclines and taxanes.
